Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aducanumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms PRIME
  • Sponsors Biogen

    • Most Recent Events

    • 26 Apr 2022 Results assessing whether aducanumab-induced reduction in brain amyloid beta (AB) plaques and downstream biomarkers of Alzheimer's disease (AD) are associated with slowed clinical decline from PRIME, EMERGE, and ENGAGE studies presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 26 Apr 2022 Results assessing demographic and baseline clinical characteristics, evaluate amyloid positron emission tomography (PET) biomarker levels, and analyze the effect of amyloid clearance on clinical measures following the off-treatment gap preceding the EMBARK study (NCT04241068) in participants formerly enrolled in EMERGE (NCT02484547), ENGAGE (NCT02477800), or PRIME (NCT01677572) presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 03 Nov 2021 According to a Biogen media release , data from this trial will be presented at the upcoming annual Clinical Trials on Alzheimers Disease conference (CTAD)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top